RAZADYNE® ER (galantamine hydrobromide) is indicated to treat the symptoms of mild to moderate dementia of the Alzheimer's type. In clinical trials, RAZADYNE® ER helped many people maintain cognitive skills (thinking and memory) and the ability to accomplish daily living activities. Also, RAZADYNE® ER is taken once daily.
In clinical trials, the most frequent adverse events with RAZADYNE® ER were nausea, vomiting, diarrhea, loss of appetite, and weight loss. Typically, these side effects were mild and temporary.
RAZADYNE® ER may not be for everyone. Some people experience a slowed heart rate, which may lead to fainting. Serious stomach problems can occur in people taking medications such as (NSAIDs) or those at risk for stomach ulcers.
For more information please visit www.RazadyneER.com.
| |
|
IMPORTANT SAFETY INFORMATION
The most common side effects with RAZADYNE®/RAZADYNE® ER are nausea, vomiting, diarrhea, loss of appetite, and weight loss. Typically, these side effects are mild and temporary.
RAZADYNE®/RAZADYNE® ER may not be for everyone. Some people experience a slowed heart rate, which may lead to fainting. Serious stomach problems can occur in people taking medications such as nonsteroidal anti-inflammatory drugs (NSAIDs) or those at risk for stomach ulcers.
Please see full US Prescribing Information.
|
|
